Design Experiments From Reported Results

 Quick Analysis Plan Copied

 Long Analysis Plan

Stage 1 — Evidence anchoring

The premise is broadly supported but must be quantified: in rhesus macaques, IFN-α/β and Mx are strongly induced in spleen, lymph nodes, and thymus during acute and chronic SIV infection, yet higher IFN-α/β expression does not correlate with viral control; Mx closely tracks tissue vRNA, serving as a biomarker rather than a protective readout SIV tissue IFN-α/β and Mx kinetics. This directly supports 'timing' as a lever: transient early induction may help, chronic induction may not.

Stage 2 — Delivery lever: nanoparticle release modeling

Tissue delivery is constrained by formulation. PLGA nanoparticle data provide the only quantitative delivery parameters available here: PLGA IFN-α nanoparticle release study

Bioinformatics task: fit release kinetic models (burst + diffusion terms) to these formulations and simulate tissue IFN-α concentration-time curves to define 'short pulse' windows (hours–days) vs chronic exposure.

Stage 3 — Signaling resistance and context sensitivity

Two mechanisms make untargeted IFN-α risky or futile: (1) constitutive SOCS3 blocks STAT1 phosphorylation and ISGF3 activation, conferring IFN-α resistance in CML lines and blast-crisis patient samples SOCS3-mediated IFN-α resistance; (2) in HCV, IFN-λ4-driven ISG15/USP18 upregulation blocks IFN-α signaling, reversible by DAAs IFN-λ4 blockade of IFN-α signaling. Include SOCS3/USP18/ISG15 induction as negative-feedback covariates in any single-cell model of reservoir hit.

Stage 4 — Immune activation risk (the counter-lever)

Chronic IFN-α is pro-inflammatory: IFN-α synergizes with apoptotic microparticles to drive IL-6/TNF-α/IL-8 and STAT1 activation in monocytes via SCARF1 IFN-α + microparticle inflammation synergy, and TNF/IFN cross-regulation shows blocking one axis elevates the other TNF/IFN-α cross-regulation. Model immune activation (cytokine scores, pSTAT1, Mx) as a risk function that grows with exposure duration and tissue breadth.

Stage 5 — Integrated analysis pipeline

• Ingest: macaque SIV tissue time-series (scRNA/bulk), PLGA release data, SOCS3/USP18 perturbation signatures.
• Model: simulate pulse duration × subtype × delivery (PLGA vs free IFN) as a 3-parameter grid; outputs: predicted reservoir-hit probability (ISG peak in latent cells) vs immune-activation cost (Mx/cytokine integral).
• Validate: hold out nonprogressor macaques (25402, 31423) whose low vRNA + low IFN-α/Mx pattern tests whether low chronic IFN-I correlates with smaller reservoirs.
• Sensitivity: vary SCARF1-dependent inflammation and SOCS3/USP18 feedback; report uncertainty intervals.

Blind spots: no direct HIV-reservoir quantification exists in these records; subtype-specific anti-HIV IFN-α potency is asserted but not measured here; macaque-to-human extrapolation is uncertain (mRNA-only IFN readouts, small n per group). Race does not intrinsically alter IFN-α signaling in healthy T cells Race and IFN-α response study, so stratify by disease context, not demographics.